Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:2 Issue:4 Number:50 ISSN#:2563-5476
RCT
ACE Report #275
Ace Report Cover Arthroplasty

Dabigatran is an inferior thromboembolism prophylactic treatment compared to enoxaparin


How to Cite

OrthoEvidence. Dabigatran is an inferior thromboembolism prophylactic treatment compared to enoxaparin . ACE Report. 2013;2(4):50. Available from: https://myorthoevidene.com/AceReport/Report/275

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery

J Arthroplasty. 2009 Jan;24(1):1-9. Epub 2008 Apr 14

Contributing Authors: RE-MOBILIZE Writing Committee JS Ginsberg BL Davidson PC Comp CW Francis RJ Friedman MH Huo JR Lieberman JE Muntz GE Raskob ML Clements S Hantel JM Schnee JA Caprini

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

1896 patients scheduled to undergo total knee arthroplasty were randomized to one of three thromboembolism prophylaxis treatments to determine the best prophylaxis option. Patients either received an oral 220 mg dose of dabigatran once daily, an oral 150 mg dose of dabigatran once daily, or a 30 mg injection of enoxaparin twice daily. The results from this study indicated that both treatments of d...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE

Please Login or Join to leave comments.